| Product Unit Size | Cost | Quantity | Stock |
|---|
Imatinib is an anticancer chemotherapeutic compound that inhibits Abl, c-Kit, and PDGFR; it is used clinically to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). In cellular assays, imatinib accelerates erythroblast differentiation and inhibits melanogenesis.
| Cas No. | 152459-95-5 |
|---|---|
| Purity | ≥99% |
| Formula | C29H31N7O |
| Formula Wt. | 493.62 |
| Chemical Name | Imatinib |
| IUPAC Name | 4-[(4-Methyl-1-piperazinyl)methyl]-N-(4-methyl-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}phenyl)benzamide |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Wang Y, Zhao Y, Liu L, et al. Inhibitory effects of imatinib mesylate on human epidermal melanocytes. Clin Exp Dermatol. 2014 Mar;39(2):202-8. PMID: 24479586.
D'allard D, Gay J, Descarpentries C, et al. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One. 2013 Apr 23;8(4):e60961. PMID: 23637779.
Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003 Feb;4(2):75-85. PMID: 12573349.
